December 2, 2019 Leading health system leverages Philips diagnostic imaging and patient monitoring solutions to deliver on Quadruple Aim: better outcomes, increased efficiency, and improved patient and staff experience Andover, U.S. and Mullica Hill, U.S. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Inspira Health (Inspira), today […]
Financial
Hemostemix Announces Appointment of Director
CALGARY, Alberta, Nov. 29, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, announces the appointment of Mr. Thomas Smeenk, BA, to […]
Novoheart Provides Corporate Update
VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Joseph Leung resigned as Chief Financial Officer and Corporate Secretary of the Company effective immediately. Ronald Li, Chief Executive Officer, stated, “On behalf of Novoheart, I would […]
CARMAT Appoints Alexandre Eleonore as Director of Manufacturing
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the appointment of Mr Alexandre Eleonore as Director of Manufacturing. Alexandre Eleonore is a […]
Medicure Reports Financial Results for Quarter Ended September 30, 2019
WINNIPEG, Nov. 26, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2019. Quarter Ended September 30, 2019 Highlights: Recorded net revenue from the sale of AGGRASTAT® (tirofiban hydrochloride) of $5.3 million during the quarter ended September 30, 2019 compared to $7.0 million for the […]
Mesoblast Financial Results for the Quarter Ended September 30, 2019
Continued Increase in Revenues and Strong Balance Sheet MELBOURNE, Australia and NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported operational highlights and financial results for the first quarter ended September 30, 2019. Mesoblast Chief Executive Dr Silviu Itescu stated: “The Company’s financial results for […]
Resverlogix Announces Warrant Exercise Incentive Program
CALGARY, Alberta, Nov. 25, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announces a warrant exercise incentive program (“Incentive Program”) designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company. The Incentive Program does not apply to warrants held by […]
Itamar™ Medical Reports Record Third Quarter 2019 Revenues
– Third Quarter Revenues Increase 33% to $8.1 Million – – WatchPAT™ Revenues Increase 32% in the Third Quarter to $7.6 Million – – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT – CAESAREA, Israel, Nov. 26, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: […]
Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of cardiovascular events1 First-in-class siRNA biological mechanism enables unique twice-yearly, subcutaneous dosing regimen and seamless integration into […]
Heartseed Raises $26M in Series B Funding to Accelerate Development of iPSC-derived Regenerative Medicine for Heart Failure
TOKYO–(BUSINESS WIRE)–Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has raised 2.8 Billion-yen (approx. $26 Million) at Series B round, bringing its total financial backing to 3.8 Billion yen (approx. $35 Million) since it was founded in 2015. […]



